Akademiliv

Sahlgrenska akademins nyheter

På Svenska
University of Gothenburg Logotype
  • News
  • Notices
  • Calendar
  • Grants
  • About Akademiliv
”Vi som arbetar med immunterapi känner oss som pionjärer. Det känns fortfarande magiskt att immunterapi sannolikt botar 20 procent av patienterna”, säger Max Levin, läkare och forskare på onkologen Sahlgrenska. Max syns längst till vänster i bild.

Immunotherapy saves many lives – but could help even more people

11 December, 2018

RESEARCH. This year’s Nobel Laureates in Medicine have revolutionized the treatment of cancer with immunotherapy, which means that one out of five patients with metastatic skin cancer can be cured. But half of the patients with metastatic malignant melanoma are not helped by the new treatment. Researchers at the Sahlgrenska Cancer Center and on the Melanoma Team at Sahlgrenska University Hospital are working together in an attempt to understand why immunotherapy has such varied effects for different patients.

Nobel Laureates in Medicine 2018, James P. Allison and Tasuku Honjo.

The success from immunotherapies developed by this year’s Nobel Laureates in Medicine, James P. Allison and Tasuku Honjo are very encouraging. The researchers worked with separate proteins, called CTLA-4 and PD-1. These proteins are located on the surface of the immune cells known as T cells, where they inhibit the ability of immune cells to recognize and attack cancer cells. Using antibodies, both Nobel Laureates succeeded in curbing these inhibitory proteins, accelerating the ability of the immune cells to kill cancer cells. Immunotherapy, also known as checkpoint therapy, was born.

“When we saw the clinical results of immunotherapy, we realized that we had to further develop the animal models we use in our research,” says Jonas Nilsson, professor, researcher and director of Sahlgrenska Cancer Center.

Lisa Nilsson pipettes to start enzymatic reactions. PhD student Elin Forsberg is at work in the background.

An aggressive skin cancer

Jonas Nilsson is also the group leader at Sahlgrenska Translational Melanoma Group, SATMEG, which brings together researchers and medical doctors researcher melanoma at Sahlgrenska University Hospital and Sahlgrenska Cancer Center. Metastatic malignant melanoma is an aggressive skin cancer, which historically has had a high mortality rate. Previously 70 percent of patients died within a year of diagnosis. But when immunotherapy with checkpoint antibodies was introduced, it revolutionized treatment.

At Sahlgrenska Cancer Center, Lisa Nilsson, who runs the research team’s lab, is assembling a reaction plate.

“We are trying to develop new treatments for metastatic melanoma and pancreatic cancer. The best way to cure cancer is by activating the immune system, but the immune cells need help,” she says.

Lisa is done with the enzymes in the latest cell cultures. The immune system gets a boost by the weakening of the tumor cells or by strengthening the ability of the immune cells, or combining both strategies.

Identifying differences

“To find out what types of help the immune system of a given patient should receive, we are developing personalized animal models and are starting clinical trials with patients. With these animal models, we are in the forefront internationally,” says Jonas Nilsson:

“We are building up a living biobank where melanoma patients can be linked with a mouse that becomes a kind of avatar for the patient’s cancer. The mouse has the same combination of immune system and cancer that the patient has. This is especially important for patients who do not respond to immunotherapies.”

The researcher Suman Mitra and Professor Jonas Nilsson are conferring while Suman centrifuges samples and starts a ChIP assay.

Researches around the world are trying to find answers to why immunotherapy is so effective for some people with metastatic malignant skin cancer but has no effect on half the patients? What is it that distinguishes these groups from an immunological perspective?

“It is these differences we are trying to identify,” says Max Levin, who is an oncologist and principal investigator in the Wallenberg Laboratory at Sahlgrenska.

All are offered treatment

Max Levin and his colleague Sara Bjursten discuss x-ray images from a patient with brain metastases that have had a good effect of antibodies against CTLA-4 and PD-1. “The patient had several autoimmune side effects, but the metastases stopped growing and now the patient is feeling excellent”, says Sara Bjursten.

Along with his colleague, Sara Bjursten, Levin is studying exactly how side effects and results of immunotherapy are connected. Because the immune system is activated by the treatment, the patient can experience severe autoimmune reactions. This suggests that there are common mechanisms behind autoimmune reactions and the tumor-inhibiting effect.

“Our goal is to identify these mechanisms by focusing on the patient’s T cells in the immune system,” Sara Bjursten says. “We collect blood, skin and tumor biopsies, excrement and urine samples from the patients. In cellular and animal experiments, we then study how autoimmune reactions are connected with treatment responses.”

Today essentially all patients are offered immunotherapy, despite the fact that half do not respond to the treatment. There is a lack of biomarkers that can determine whether or not the treatment will produce results.

“We also perform an advanced mapping of the patient’s gastrointestinal microbial flora (‘the gut microbiota’), which plays an important role in the immune system. Previous studies show that there is a connection between the gut microbiota and responses to immunotherapy,” says Max Levin.

The project requires many different areas of expertise, which is why Levin and Bjursten collaborate with researchers at the Sahlgrenska Department of Rheumatology, Sahlgrenska Cancer Center, Chalmers University of Technology, MetaboGen biotech company and Wallenberg Laboratory.

Intractable liver metastases of ocular melanoma

“Depending on the treatment, it takes about an hour. It is possible to combine PD-1 inhibitors with CTLA-4 inhibitors. In patients with melanoma, the effect is greatest if both proteins are blocked simultaneously, ”says Lars Ny, showing how the treatment is conducted, along with PhD student Henrik Jespersen.

At the Department of Oncology at Sahlgrenska, Chief Physician and Associate Professor Lars Ny and Henrik Jespersen, resident in oncology and PhD student, demonstrate what happens when patients receive immunotherapy. With his background as a clinical pharmacologist and director of the clinical trials unit, Lars Ny has extensive experience with clinical trials. He is section head of the melanoma team and is responsible for the clinical part of research at SATMEG. Ny is working on ocular melanoma, an intractable disease in which the cancer first occurs inside the eye and then spreads, often to the liver. In the project he works together with Jonas Nilsson to characterize eye melanoma, because these patients currently are not helped by immunotherapy with only checkpoint inhibitors. The researchers are also testing combining PD-1 inhibitors with HDAC inhibitors in a clinical trial to see if immunotherapy can also produce better results for ocular melanoma.

“We hope that HDAC inhibitors will reprogram the hidden cancer cells, making them visible to the immune cells so that the immunotherapy works,” says Lars Ny.

So far 29 patients are testing this form of treatment. The first phase is completed, and a report is currently being finalized for publication.

Can eliminate cancer

What do melanoma researchers think about immunotherapies up until now? They seem to agree that immunotherapies have meant more for melanoma patients than any previous treatment.

“We do not have to start from scratch. With some patients, we can eliminate the cancer, and for others we can at least prolong life. I regard immunotherapies as a starting point for further treatment,” says Jonas Nilsson.

“Because the results are so good, we will continue to develop immunotherapies until we find a cure,” says Lars Ny.

“I believe that immunotherapy will also work in cancers where you do not see any results today,” says Max Levin.

Lars Ny och Max Levin.

The traditional treatment alternatives (radiation, anti-cancer drugs, surgery and targeted treatments) are also available but are being used less often.

Even if metastatic cancer is still a disease that is fatal for many patients, the work still seems meaningful, they say.

“Our commitment and knowledge make a difference for patients and relatives. We are working to ensure that they receive the best possible treatment and care,” Ny says.

“The driving force is to advance the state of knowledge and to provide patients in the Västra Götaland region with the most modern treatment possible,” Jonas Nilsson concludes.

Fakta

  • About 4,000 people contract malignant melanoma in Sweden each year. Of those, between 500 and 600 have a metastatic form of the disease.
  • Sahlgrenska Cancer Center is a Center of Expertise and Research at Medicinareberget. SATMEG, Sahlgrenska Translational Melanoma Group, is a collaboration among Jonas and Lisa Nilsson’s laboratory, surgeon Roger Olofsson Bagge and oncologists Lars Ny and Ulrika Stierner. The melanoma team at the Jubilieum Clinic, Sahlgrenska University Hospital Department of Oncology, consists of Lars Ny, Ulrika Stierner, Sara Bjursten, Henrik Jespersen and Max Levin. Max Levin heads his own research team in the Wallenberg Laboratory and is not a member of SATMEG, though he collaborates with it.
  • For more info: www.satmeg.se

TEXT AND PHOTO: ANNA REHNBERG

By: Elin Lindström
Tagged With: cancer, cancer, Cancerforskning

Add your own events in the Akademiliv Calendar

No newsletter during the sports holiday – Wednesday, February 15

Information from Sahlgrenska Academy Research Support Office

[UPDATED JAN 24]
The Sahlgrenska Academy Research Support Office provides an overview of upcoming and current calls, nominations and events in an information letter. This letter is updated approximately four times per semester.

’20 minutes for researchers’ is back – see full spring program

During 20 minutes over Zoom, the Biomedical Library gives tips on tools and services that can facilitate your research everyday life.

We are building at Medicinareberget

You will now find comprehensive information on construction projects that affect the Sahlgrenska Academy in the Staff Portal.

Lunch menus

Café Anatomen
Menu not available on website.

Café Annedal
Menu not available on website.

Lunchen.nu

Lustgården på Änggårdsbacken
Take away for external guests between 11.00-12.30 weekdays.

Lyktan

Mersmak Mölndal

Mersmak Sahlgrenska

Mersmak Östra

Salt & Syra

More news

New thesis: Higher risk of future accidental bowel leakage after sphincter injury

3 February, 2023

THESIS. A study that was part of a recent doctoral thesis at the Institute of Clinical Sciences reports a significantly higher risk of developing …  

Formal ceremony for Zealous and Devoted Service

3 February, 2023

ACADEMIC CEREMONIES. On Wednesday, January 25, the University invited a 68 staff members to a ceremony to receive their Zealous and Devoted …  

Nominations for Honorary Doctors 2023 is open

2 February, 2023

HONORARY DOCTOR. All staff at Sahlgrenska Academy may nominate honorary doctorates. The appointments are evidence of the faculty’s appreciation, a …  

Depression and low quality of life 30 years after chemical attack

27 January, 2023

NEW STUDY. Mustard gas harms the vision, skin and breathing. Three decades on, however, the predominant effect is mental ill-health. At a time …  

Testing a immunological drug as a new treatment for early type 1 diabetes

26 January, 2023

CLINICAL STUDY. A large clinical study is now beginning on an approved drug for treating psoriasis. The drug will be tested on patients who were …  

Emma Eckernäs: GU now surveying doctoral students’ work environment too

25 January, 2023

COLUMN. For the first time, the work environment survey (ARK) at the University of Gothenburg (GU) now contains a sub-survey aimed specifically …  

Nominate for the award “PhD Thesis of the Year”

24 January, 2023

AWARD. Do you know of a really good thesis that was defended last year? Until February 7, you can nominate for the Sahlgrenska Academy's PhD …  

New legislation for clinical trials of medicinal products

24 January, 2023

RESEARCH RESOURCES. New EU legislation for clinical trials of medicinal products will be phased in over the coming years. All new applications …  

Joining forces for research on asthma, allergy, and airways

24 January, 2023

RESEARCH CONDITIONS. "Breathe Sweden", a digital platform for researchers who collect studies on diseases and disorders of the respiratory tract, …  

Fewer surgically treated ankle fractures with a clear-cut treatment routine

24 January, 2023

DOCTORAL THESIS. It has been shown that the percentage of ankle fractures that undergo surgery could be substantially reduced, from more than 30 …  

More news...

Sahlgrenska Academy

© University of Gothenburg
PO-Box 100, S-405 30 Gothenburg, Sweden
Phone: 00 46 31 786 0000

About the website

Elin Lindström is editor for Akademiliv.
Please feel free to send your ideas and comments to akademiliv@gu.se

Sign up for the Akademiliv newsletter:

Send you tips to Akademiliv

Do you have a suggestion for news, grants, seminars or an education?
Send an email to Elin Lindström Claessen